Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 2 4Phase 1 4

Status

Unknown 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 24Breast Neoplasms 15Sarcoma 9Myelodysplastic Syndromes 9Carcinoma, Non-Small-Cell Lung 9Stomach Neoplasms 8Multiple Myeloma 7Leukemia, Myelomonocytic, Chronic 7Myeloproliferative Disorders 6Uterine Cervical Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Recurrence 4Prostatic Neoplasms 4Neoplasms 4Melanoma 4Lung Neoplasms 4Leukemia, Monocytic, Acute 4Head and Neck Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Advanced Solid Tumour 4Stomatitis 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Mucositis 3Leukemia, Myelomonocytic, Acute 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Cholangiocarcinoma 3

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Injections × Clear all
NCT04722575 2025-03-13

NEO-TIM

Fondazione Melanoma Onlus

Phase 2 Active not recruiting
95 enrolled
Dermatologic

Melanoma

NCT06500091 2024-07-15

TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Not yet recruiting
54 enrolled
DermatologicSarcoma

Melanoma, Sarcoma

NCT05135715 2024-02-20

A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

RemeGen Co., Ltd.

Phase 2 Unknown
50 enrolled
Dermatologic

Melanoma

NCT04593485 2020-12-23

Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract

Fudan University

Phase 2 Unknown
40 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡